Past sessions 

Date: October 5, 2021
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific
Presented by: Brad Roberts

Brad Roberts is an assistant professor of Emergency Medicine at the University of New Mexico and actively practices Emergency Medicine with Southern Colorado Emergency Medicine Associates in Pueblo, Colorado. He has written a peer reviewed review article reviewing cannabis that was published in the Western Journal of Emergency Medicine and was cited by 23 news outlets including Yahoo News, MSNBC, USA Today, and others. He has authored a chapter in Cannabis in Medicine. He has given lectures regarding cannabis across the United States and to multiple legislative bodies in multiple states. He has written multiple articles in ACEPNow (American College of Emergency Physicians newsletter), newspapers, and other publications. He has appeared in multiple documentaries and podcasts regarding cannabis. He has 3 wondeful children and a wife who are the loves of his life. He likes to be outdoors and also spends time advocating for nature as medicine advocating for people to spend more time outdoors for the myriad health benefits this affords.

We will review common Emergency Department presentations related to cannabis and include a broad overview of adverse health outcomes related to cannabis use.

Moderated by: Libby Stuyt

Date: October 12, 2021
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific
Presented by: Crystal Collier

Dr. Collier’s comprehensive prevention model, which teaches the neurodevelopmental effects of risky behavior to children, teens, teachers and parents, was selected for the 2015 Prevention and Education Commendation from the National Council on Alcoholism and Drug Dependence. In 2018 she received the Torch Bearer Award for her work in the field of addiction from the Texas Association of Addiction Professionals. In the same year, The Hope and Healing Center and Institute in Houston, TX, granted Dr. Collier a research fellowship to support the completion of The NeuroWhereAbouts Guide. In 2019, she received the Outstanding Research Award from the Association of Alternative Peer Groups and was acknowledged as Counselor of the Year by the Houston Counseling Association.

The webinar will review how the brain becomes addicted to marijuana, the implications for executive functioning and application of prevention principles for clinicians and parents.

Moderated by: Libby Stuyt

Date: October 19, 2021
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Jacci Bainbridge

Jacquelyn L. Bainbridge, BSPharm, PharmD, FCCP, MSCS, FAES, is a Professor at the University of Colorado Anschutz Medical Campus, where she holds joint appointments in the Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Clinical Pharmacy, and the Department of Neurology in the School of Medicine. Dr Bainbridge received her doctorate in pharmacy from the University of Colorado in Denver, where she subsequently completed a specialty residency in neurology.

We will start the session by reviewing cannabis pharmacology.
Discuss up to date data about medical cannabis and cannabidiol, including over the counter products and drugs approved as prescriptions.
We will describe the role of cannabis in neurology and psychiatry. The webinar will review how the brain becomes addicted to marijuana, the implications for executive functioning and application of prevention principles for clinicians and parents.

Moderated by: Kenneth Finn

Date: October 26, 2021
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific
Presented by: Kenneth Finn

Kenneth Finn, MD has been practicing Pain Medicine in Colorado Springs since 1994. He is Board Certified in Physical Medicine and Rehabilitation (1995), Pain Medicine (1998), and Pain Management (2000). He is President-Elect (2020) to the American Board of Pain Medicine. He served on the Colorado Governor’s Task Force on Amendment 64, which legalized marijuana for recreational use, Consumer Safety and Social Issues Work Group (2012) and serve 4 years on Colorado’s Medical Marijuana Scientific Advisory Council (2014-18). He has testified to the Canadian Senate on their marijuana bill (2018) and speaks internationally on the health impacts of marijuana, including being an invited to the Mayo Clinic, Jacksonville, the Royal College of Surgeons in Ireland, and the Texas Medical Society. He is editor of Cannabis in Medicine: An Evidence-Based Approach (2020) and currently the Co-Vice President (2021) of the International Academy on the Science and Impacts of Cannabis (

The relationship between the endocannabinoid and opioid system will be described and the associated public health and safety concerns will be outlined.

Moderated by: Libby Stuyt

Date: November 4, 2021
Time: 4:00PM - 5:00PM Eastern / 1:00PM - 2:00PM Pacific

Presented by: Robert Page

Dr. Page is Professor in the Departments of Clinical Pharmacy , Medicine, and Physical Medicine at the University of Colorado Schools of Pharmacy and Medicine. He has been a clinical pharmacy specialist for the Division of Cardiology Section of Advanced Heart Failure and Heart Transplant for 23 years and has published over 200 peer-reviewed manuscripts, book chapters, and abstracts in the management of patients with cardiovascular disease. He is a Fellow of the American Heart Association, Heart Failure Society of America, American College of Clinical Pharmacy, and the American Society of Health System Pharmacists.

This session will explore the metabolism of THC and CBD in cannabis which in turn impacts potential/documented drug drug interactions, as well as, potential interactions to address these with patients.

Moderated by: Catherine Antley

Date: November 9, 2021
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: LaTisha Bader

Dr. Bader has worked in a variety of treatment settings including residential, outpatient, private practice, and Native American health care. She spends time in the sport environment in collegiate athletic departments, working with professional teams, and Olympic athletes. She currently compliments the multi-disciplinary team at Women’s Recovery by serving as the Chief Clinical Officer, advancing treatment for women. In addition, she maintains a private practice offering counseling, consultation, educational presentations, and sport psychology services. She authored a chapter in the evidenced based book, Cannabis in Medicine. She serves on the Speakers Bureau for the National Marijuana Initiative as a subject matter expert on emerging research, addiction and treatment.

This presentation will outline the rapidly changing culture of cannabis use highlighting potency and routes of administration, perception of risk, and common exchanges regarding substance use and women’s issues. It will share popular products marketed to women and campaigns targeted to female identified individuals. It will review public health concerns including child protective services, health concerns of using during pregnancy and breastfeeding, as well as the influence on self and family, and how to have an intelligent “cannabis conversation.”

Moderated by: Kenneth Finn

Date: November 16, 2021
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Laura Stack and Libby Stuyt

Laura Stack’s 19-year-old son, Johnny, died by suicide on November 20, 2019, after becoming delusional from dabbing high-THC marijuana concentrates. Soon afterward, Laura started a 501c3, Johnny’s Ambassadors, to educate parents and teens about the dangers of today’s high-THC marijuana on adolescent brain development, mental illness, and suicide. In this session, Laura will share the story of Johnny’s marijuana addiction from a parent’s point of view.

Then Dr. Libby Stuyt will provide the scientific-based research on the correlation between cannabis, psychosis, and suicide. Dr. Stuyt will include the evidence that high-potency concentrates, such as what Johnny was using, are the worst culprits, and how we have attempted to put some controls on these with legislation in Colorado.

Moderated by: Catherine Antley

Date: November 23, 2021
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Brian Miller

Dr. Miller currently focuses on clinical schizophrenia research, including inflammation/immune dysfunction, cardiometabolic abnormalities, and insomnia. He is currently funded by the NIMH and Stanley Medical Research Foundation, and has over 100 peer-reviewed publications. Dr. Miller has been recognized with several awards, including a 2011 Exemplary Psychiatrist Award from the National Alliance on Mental Illness, the 2015 Augusta University Outstanding Young Clinical Science Faculty Award, and the 2017 OSU College of Medicine Early Career Achievement Alumni Award. He is an editorial board member of Schizophrenia Bulletin, BMC Psychiatry, and Psychiatric Times. In addition to his research, Dr. Miller provides clinical care for patients with schizophrenia, and supervises and teaches residents and medical students in general psychiatry.

Substance use comorbidity in psychotic disorders has been described as “the rule rather than the exception”, and is often deleterious to the clinical course of illness. Cannabis (marijuana) is one of the most commonly used substances by patients with schizophrenia and related psychotic disorders. Modulation of the endocannabinoid system by the main psychoactive component in marijuana, Δ9-tetrahydrocannabinol, can induce acute psychosis and cognitive impairment. Over the past two decades, there has been extensive research on the association between cannabis and psychosis. The purpose of this presentation is to synthesize recent research in this area, including associations between cannabis and psychosis risk; the epidemiology and phenomenology of psychosis and comorbid cannabis use; and associations between cannabis use and clinical course, and outcomes in psychosis.

Moderated by: Catherine Antley

Date: December 1, 2021
Time: 10:00AM - 11:00AM Eastern / 7:00AM - 8:00AM Pacific

Presented by: Emily Kline

Dr. Emily Kline is a psychologist, an assistant professor of psychiatry at Boston University School of Medicine, and the director of psychological services for the Wellness and Recovery After Psychosis Clinic at Boston Medical Center. She is an expert on early intervention in psychosis and the needs of families dealing with mental illness. Her research focuses on mental health care access, treatment outcomes, and family communication. Dr. Kline also enjoys writing and speaking for popular audiences about young adult development and family communication.

A communication strategy called motivational interviewing is widely used by health professionals to enhance people’s motivation to make healthy changes. Dr. Emily Kline has developed a motivational interviewing-inspired curriculum for parents of teens and young adults struggling with issues ranging from substance use to school refusal to serious mental illness. In this workshop, Dr. Kline will teach attendees about the principles of motivational interviewing and share how parents can use these skills to have closer relationships and more productive conversations with their teen and young adult children.

Moderated by: Catherine Antley

Date: December 8, 2021
Time: 10:00AM - 11:00AM Eastern / 7:00AM - 8:00AM Pacific

Presented by: Thida Thant

Dr. Thida Thant is an assistant professor and consultation-liaison (CL) psychiatrist at the University of Colorado Department of Psychiatry. She graduated with a Bachelor of Arts Degree in Plan II honors from the University of Texas at Austin, attended medical school at the University of Texas Medical School in Houston and completed her general adult psychiatry residency and psychosomatic medicine fellowship at the University of Colorado. She is currently the director of the University of Colorado Consultation-Liaison Psychiatry Service and the Psychiatric Consultation for the Medically Complex clinic (PCMC) in the Department of Psychiatry at the University of Colorado Anschutz Medical Campus. Her academic interests include marijuana and its impact on psychiatric practice in states with legalized marijuana, the creation and implementation of marijuana curricula in medical education and psychiatric care for medically and neurologically complex patients. She has spoken at multiple conferences on the topics of chronic medical illness, marijuana and consultation-liaison psychiatry, has authored book chapters about cannabis in books such as Marijuana and Mental Health and Cannabis in Medicine and has developed and published a cannabis curriculum through AAMC's MedEdPortal titled "What You Need to Know About Cannabis: An Evidence-Based Crash Course for Mental Health Trainees."

This session will review literature regarding cannabis and it's impact on various mental health disorders. It will discuss how to consider the current state of literature in the context of your patient's clinical presentation, how to evaluate the risk/benefit in your patient and how to approach psychoeducation regarding the impact of cannabis on mental health disorders such as depression, bipolar, anxiety, sleep and psychosis.

Moderated by: Libby Stuyt

Date: December 14, 2021
Time: 3:00PM - 4:00PM Eastern / 12:00PM - 1:00PM Pacific

Presented by: Stuart Reece

Dr. Stuart Reece is a family physician working in Brisbane in Australia where he runs a large clinic with a special interest in the medical treatment of drug addiction. He is interested both in the underlying pathophysiology of drug addiction – how drugs work in the body and why they are so destructive to long term health – and also in the treatment of drug addiction including its radical cure.

Dr Reece has a long standing interest in cannabinoids particularly as they relate to genotoxicity, epigenotoxicity and chromosomal and mitochondrial toxicity which have downstream effects lasting for multiple generations. For these reasons Dr Reece has published several epidemiological research papers on cannabis-induced genotoxicity as reflected in the incidence of both birth defects and cancer development both in exposed adults and in the offspring of exposed individuals and subsequent generations.

Dr Reece extensively uses advanced space-time statistical analytical techniques and the formal techniques of causal inference to analyze not just associations across space and time simultaneously but also to quantitatively evaluate the evidence for truly causal relationships.

Dr. Reece was appointed and now re-appointed a Professor in the School of Psychiatry and Clinical Neurosciences at both the University of Western Australia and Edith Cowan University in recognition of his many contributions which advance our understanding of the toxicopathophysiology and treatment of drug addiction in general and cannabinoid exposure in particular.

Moderated by: Roneet Lev

Date: December 28, 2021
Time: 2:00PM - 3:00PM Eastern / 11:00AM - 12:00PM Pacific

Presented by: Jean Hausheer

Dr. Hausheer practices comprehensive cataract and refractive eye care in Lawton Oklahoma with a predominantly native American, military, and rural patient base as Clinical Professor Dept of Ophthalmology, with the Dean McGee Eye Institute, affiliated with the University of Oklahoma. She also works as Adjunct Clinical Professor of Rural Health with Oklahoma State University Family Medicine and Emergency Medicine residency programs in Lawton.
She obtained her medical degree from the University of Missouri Kansas City School of Medicine, and Internship and Ophthalmology residency training at the Mayo Clinic in Rochester Minnesota.

The endocannabinoid system strongly influences a wide variety of physiologic processes within the human body by targeting specific receptors in most organ systems, including the ocular system. Glaucoma is an optic neuropathy that has a wide variety of risk factors, but only one controllable factor: intraocular pressure. There is an ongoing scientific effort to investigate if targeting the ocular endocannabinoid system can effectively treat this and other blinding diseases affecting the human eye. Marijuana is a drug with numerous molecular components, some well characterized and others poorly studied, that has inconsistent effects on intraocular pressure. As things currently stand, there is a lack of scientific evidence that effectively demonstrates marijuana as a useful monotherapy or a superior treatment option to treat glaucoma, as compared to traditional treatment modalities like topical or oral medications, laser, or glaucoma surgery. As legalization of marijuana increases across the United States and other North American countries, it is paramount for physicians and the lay public, to understand the effects of marijuana and other endocannabinoids on the ocular system, and patient perceptions and concerns regarding treatment of eye disease with these substances.

Moderated by: Kenneth Finn

Date: January 6, 2022
Time: 4:00PM - 5:00PM Eastern / 1:00PM - 2:00PM Pacific
Presented by: Bertha Madras

Bertha K Madras, PhD, Professor of Psychobiology at Harvard Medical School (35 years), is based at McLean Hospital and cross-appointed at the Massachusetts General Hospital. She directs the Laboratory of Addiction Neurobiology at McLean Hospital. Her experiences in neuroscience research, drug addiction, education, government and public service offer a unique perspective at the intersection of science and public policy. Her research focuses on neurobiology, pharmacology, brain imaging, drug discovery for addiction, neuropsychiatric disorders, and drug policy. She is author of more than 200 scientific manuscripts, articles, book chapters and co-editor of books: “The Cell Biology of Addiction”; “Effects of Drug Abuse on the Human Nervous System”; “Imaging of the Human Brain in Health and Disease”.
She is a recipient of 19 U.S. and 27 international issued patents with collaborators. She served as Deputy Director for Demand Reduction in the White House Office of National Drug Control Policy (ONDCP), Executive Office of the President, a presidential appointment confirmed unanimously (99-0) by U.S. Senate. In a 2015 landmark Federal Court case, she served as the sole expert witness for U.S. Department of Justice in de-scheduling of marijuana. In 2017, she was appointed as one of six members of the President’s Commission on Combating Drug Addiction and the Opioid Crisis along with Govs. C. Baker (MA); C.. Christie, (NJ, ret.); R. Cooper (NC); Congress. P. Kennedy (RI, ret.); Attorney General P. Bondi (FL, ret.) She currently is a member of the National Academy of Medicine Collaborative on the Opioid Crisis.
She was sole author of a World Health Organization commissioned report, “Update of Cannabis and its Medical Use” (2015) and co-authored “The Health and Social Effects of Nonmedical Cannabis Use. Dr. Madras recently served as a panelist on Narcotics at the Vatican Pontifical Academy of Sciences.
Education. She developed an international course on the Cell Biology of Addiction at Cold Spring Harbor Laboratories and a museum exhibit, a CD (licensed by Disney) “Changing Your Mind: Drugs in the Brain” and play, in collaboration with the Museum of Science, Boston. She is the recipient of research and public service awards, to include a NIDA Public Service Award, CPDD Innovator Award, and a 2006 Better World Report designation of her brain imaging invention as “one of 25 technology transfer innovations (university to industry) that changed the world”.

This session will cover:

1. The endocannabinoid system in the body is a primary target of THC, the key cannabinoid in marijuana:
-what is the endocannabinoid signaling system?
-where is it localized?
-what are its functions?

2. How do THC and endocannabinoids act?
-what are phytocannabinoids (compounds made by plants)?
-what are THC actions in the body? (receptor targets in brain, peripheral tissues)
-do THC and opioid signaling systems crosstalk?
-do actions by THC (plant-derived) or endocannabinoids (made by brain) differ?
-does THC affect neurodevelopment?
-medical marijuana and recreational marijuana; do they differ?

3. What are the consequences of THC actions?
-does THC engender neuroadaptive changes?
-are the effects of THC related to dose and frequency of use?
-what are short- and long-term implications of marijuana?

Moderated by: Eric Voth

Date: January 25, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific
Presented by: Zerrin Atakan

After completing her psychiatric training in Hacettepe University, Turkey, Dr
Atakan moved to the UK with a research scholarship, where she obtained her
membership degree from the Royal College of Psychiatrists. From 1990 until 2003,
she worked as a psychiatric intensive care Consultant and from 2003 until 2007
was the Lead Consultant at the National Psychosis Unit at the Maudsley Hospital,
London. She works as a part-time clinician and an Honorary Senior Lecturer and a
Senior Researcher at The Institute of Psychiatry, Psychology and Neurosciences,
King’s College London, where she has been studying the effects of cannabis
compounds on behaviour and brain regions since 2000, as well as researching in
the development of an intervention model to treat those with psychosis who
continue to use substances. She has written numerous articles on the effects of
cannabis compounds in peer reviewed, high impact journals and makes frequent
presentations on psychoses and cannabis related topics.

This presentation will begin with the composition of the cannabis plant, outlining its complexity with over 400 chemicals and four major compounds. It will then provide an overview of the endocannabinoid system within the brain and the body. This will be followed by the characteristics of the adolescent brain, particularly focussing on the possible effects of THC on the pruning process. It will also provide information on the effects of cannabis use on cognitive functioning, as well as the possible induction of THC on disrupting the excitatory-inhibitory balance of neural networks.

There will then be a discussion on why some teenagers are more at risk of developing an enduring psychotic illness following the use of high-THC cannabis.

Moderated by: Kenneth Finn

Date: February 1, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Aaron Weiner

Aaron Weiner, PhD, ABPP is a board-certified Psychologist and addiction specialist, and speaks nationally on the topics of addiction, behavioral health, and the impact of drug policy on public health.   He earned his doctorate from the University of Illinois at Urbana-Champaign and completed his fellowship in Addiction Psychology at the VA Ann Arbor Healthcare System.  His perspective is informed by years of experience growing and directing addiction service lines for hospitals and healthcare systems, the current state of medical and psychological research, and his own observations in private practice.  Dr. Weiner is the President-Elect of the Society of Addiction Psychology, a member of the Physician Speakers Bureau for the National Safety Council, and on the Science Advisory Board for Smart Approaches to Marijuana.

The cannabis industry is in a state of rapid growth, with continual expansion into new products and actively working to shape public perception of their products.  Join Dr. Aaron Weiner for an exploration of future trends of cannabis in the United States, including mechanisms and implications of increased use, new products (including Delta-8 THC and THC-O Acetate), and challenges to effective clinical treatment.

Moderated by: Eric Voth

Date: February 8, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Shannon Murphy

Dr. Shannon Murphy is a pediatrician who currently volunteers her time in drug education. Dr. Murphy received her undergraduate degree at Vanderbilt University and her M.D. from Emory School of Medicine. She completed her pediatric training at the Children’s Hospital of Philadelphia and subsequently worked as a primary care pediatrician in a community group practice in Alabama. She has served on a Practice Advisory Committee on Adolescent Substance Use for the American Academy of Pediatrics and currently sits on the Board of Directors for National Families in Action (NFIA), a national non-profit substance use prevention organization. Dr. Murphy’s primary focus is on adolescent health and well-being. She is actively involved in developing education-based community outreach programs throughout the state with a concentration on marijuana education for teens, parents, and community organizations.

Psychosocial screening is an essential part of the adolescent medical visit. Recent changes in marijuana laws around the country have impacted adolescent views on marijuana and teens’ perception of harm regarding marijuana use has decreased. Currently, marijuana now surpasses tobacco use for many young people. The adolescent visit is an important opportunity to address common misperceptions regarding use. This talk will give the provider an update on today’s marijuana and includes a). a brief review of those health effects that make the adolescent population particularly vulnerable to marijuana use, b). a discussion on cultural norms and how they affect adolescent and young adult use, and c). the importance of self-efficacy in choosing healthy behaviors.

Moderated by: Catherine Antley

Date: February 24, 2022
Time: 4:00PM - 5:00PM Eastern / 1:00PM - 2:00PM Pacific

Presented by: Phillip Drum

Phillip A Drum, Pharm, D., FCSHP received his doctorate in Pharmacy from the University of California – San Francisco. He is a 30+ year licensed pharmacist who has had a wide range of experiences – from community pharmacy practice, a residency in Hospital Pharmacy, practice as a hospital-based Oncology pharmacist, Pharmacy Administration work as a Clinical Coordinator and later a Regional Manager and leader of regional pharmacy training and patient safety programs. He has been active in Pharmacy Associations and has spoken state-wide and nationally on various pharmaceutical topics. As a result of a family tragedy, he has been active in research on driving and marijuana and educating the public over the dangers of marijuana in society.

This seminar will discuss the impact marijuana use has on driving. Review of pharmacokinetics of major cannabis components. Review data from impaired driving fatalities and methods used to monitor impaired drivers.

Moderated by: Kenneth Finn

Date: February 25, 2022
Time: 11:00AM - 12:00PM Eastern / 8:00AM - 9:00AM Pacific

Presented by: Marta DiForti

Dr. Marta Di Forti is a Senior Lecturer at the Dept of Social, Developmental and Genetic Research, Institute of Psychiatry, and Honorary Consultant Adult Psychiatrist, Lambeth Community team, South London and Maudsley NHS foundation Trust. She leads the first and only Cannabis Clinic for patients with Psychotic disorders in UK. She was recently awarded a MRC Senior Research Fellowship to expand her research in the role of cannabis use in psychosis and its underlying biology. With her team she showed for the first time that use of high potency types of cannabis e.g. "skunk" carries a higher risk of psychosis than use of traditional types and that it affects rates of Psychotic disorders across Europe. Though it still remains unclear who are those cannabis use most at risk. Her future work aims to investigate the interaction between cannabis use and genes predisposing to schizophrenia, and how cannabis changes the epigenome.

Moderated by: Ken Finn

Date: March 1, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Sharon Levy

Sharon Levy, MD, MPH is a Developmental-Behavioral Pediatrician, Addiction Medicine specialist, Director of the Adolescent Substance Use and Addiction Program at Boston Children’s Hospital, and Associate Professor at Harvard Medical School. Over the past 20 years she has evaluated and treated thousands of adolescents with substance use disorders, and she has written extensively on the topic. In 2016 she established the nation’s first accredited Pediatric Addiction Medicine Fellowship training program. She has expertise in the integration of substance use treatment services into pediatric primary care.

Cannabis products continue to become more readily available across the country and as a result adolescents have increased access. This talk will focus on the health outcomes associated with cannabis use during adolescence, as well as methods for identifying and treating substance use in adolescents.

Moderated by: Catherine Antley

Date: March 8, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Robert DuPont, Ed Wood

For 50 years, Robert L. DuPont, MD has been a leader in drug use prevention and treatment. He was the first Director of the U.S. National Institute on Drug Abuse (1973-1978) and the second White House Drug Chief (1973-1977). In 1978 he became the founding President of the Institute for Behavior and Health, Inc., a non-profit research and policy organization that identifies and promotes powerful new ideas to reduce drug use and addiction. A graduate of Emory University, Dr. DuPont received an MD degree in 1963 from the Harvard Medical School. He completed his psychiatric training at Harvard and the National Institutes of Health. Dr. DuPont maintains an active practice of psychiatry specializing in addiction and the anxiety disorders and has been Clinical Professor of Psychiatry at the Georgetown University School of Medicine since 1980.

Ed Wood founded DUID Victim Voices after the death of his 33-year old son Brian at the hands of two drug impaired drivers on marijuana, methamphetamine and heroin. He has a B.S. in Chemistry from Harvey Mudd College and an MBA from University of Colorado and became the founding CEO of COBE BCT. Mr. Wood has worked with victims, prosecutors, defense attorneys, judges, clinicians, drug recognition experts, law enforcement officers, toxicologists, legislators, state officials, and an international list of researchers and other specialists in his quest to increase public knowledge about DUID. Mr. Wood has numerous peer-reviewed publications and wrote the 2017 law requiring Colorado to begin collecting and reporting data on drug-impaired driving.

This session will present data on the role of cannabis in impaired driving from the state of Colorado, ground zero for cannabis commercialization. What policies have been adopted to detect and deter cannabis-impaired driving – and have they worked? The data may surprise you. In this session, Dr. Robert DuPont and Mr. Ed Wood will discuss the policy solutions that are needed at the local, state, and national level to reduce the adverse impact of polysubstance use on our roads. 

Moderated by: Roneet Lev

Date: March 22, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Roneet Lev

Roneet Lev, MD FACEP was the first Chief Medical Officer of the White House Office of National Drug Control Policy, ONDCP, 2018-2020. She brought refreshing frontline medical experience to national health policy. She is a nationally acclaimed medical expert and speaker who continues to treat patients in the emergency department and hosts a podcast titled High Truths on Drugs and Addiction. As a mother of four she relates to families who struggle. Lev uses data to drive change and is frequently quoted in print and television media. Lev is dually board certified in emergency and addiction medicine, bringing over 25 years of experience treating the frontline cases of addiction. She came to the White House as chief of the emergency department at Scripps Mercy Hospital in San Diego. In 2012, she established and chaired the San Diego Prescription Drug Abuse Medical Task Force, the first of its kind in California that integrated physicians of various specialties along with hospitals, law enforcement, hospital administration, treatment programs and public health for the purpose of decreasing deaths and mortality from prescription drugs. Lev’s medical publications known as the “Death Diaries” studied the details of prescription patterns of people who died from accidental medication drug overdoses, giving insight to the causes of overdose and directing prevention efforts. Lev graduated from the University of Texas Medical School in San Antonio and completed her emergency medicine residency training at the University of California San Diego.

Dr. Lev served as President of the California Chapter of the American College of Emergency Physicians in 2000. She is Founder and President of IEPC, Independent Emergency Physicians Consortium, an organization providing collaboration to independent emergency departments in California. Her program on Safe Prescribing in the emergency department won the 2014 National Association of Counties award. The California US Attorney's office nominated her for the White House Champion of Change Award. Lev is an energetic leader with a passion to assist communities in preventing and treating addiction. She continues to practice medicine on the front lines and consults on clinical medicine and health policy.

Date: April 5, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Roberto Olivardia

Roberto Olivardia, Ph.D., is a Clinical Psychologist and Lecturer in the Department of Psychiatry at Harvard Medical School. He maintains a private psychotherapy practice in Lexington, Massachusetts, where he specializes in the treatment of attention deficit hyperactivity disorder (ADHD), Body Dysmorphic Disorder (BDD), Obsessive-Compulsive Disorder (OCD) and in the treatment of eating disorders in boys and men. He has spoken on numerous podcasts and webinars and presents at many talks and conferences around the country. He currently sits on the Professional Advisory Boards for Children and Adults with ADHD (CHADD) and the Attention Deficit Disorder Association (ADDA). He also serves on the Scientific Advisory Board for ADDitude and is Featured Expert on

Attention Deficit Hyperactivity Disorder (ADHD) is a condition characterized by attention dysregulation, impulsivity, hyperactivity and executive functioning issues. Cannabis is one of the most widely abused substances among people with ADHD. Studies show that those diagnosed with ADHD are more likely to develop a Cannabis Use Disorder. One study found that 34% to 46% of those seeking treatment for cannabis dependence had an ADHD diagnosis. Cannabis is not medicinal for ADHD. Cannabis carries lifelong psychological and physical consequences to the developing brain and body, and people with ADHD are especially vulnerable to its effects. This webinar will first educate viewers on the facts on ADHD, a widely misunderstood diagnosis. Understanding why people with ADHD are at higher risk for dependence will be reviewed through knowledge on the ADHD brain, as well as other psychological factors. Though marijuana use is a hotly debated topic, this webinar focuses on strong scientific studies and clinical examples to drive home the cannabis-ADHD connection, as well as important treatment implications when someone with Cannabis Use Disorder also has ADHD.

Moderated by: Kenneth Finn

Date: April 12, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Jesse LeBlanc

Jesse graduated summa cum laude from the University of Houston with a Bachelor of Science degree in Mechanical Engineering in 1998. For over 20 years, he provided services as both an employee and consultant on the inspection, repair, design, and operation of chemical, refined products (gasoline and diesel fuel), and crude oil pipelines for ExxonMobil Pipeline Company. He also performed risk assessments and hazardous operation reviews for multiple pipeline related projects. While an employee at ExxonMobil, he received numerous awards as an engineering mentor and for his novel solutions that solved several engineering problems.

Before obtaining his mechanical engineering degree, he worked for 17 years in the aircraft industry as a Federal Aviation Administration (FAA) licensed Airframe and Powerplant technician and as an Authorized Inspector. During this time period, he was certified to maintain and repair multiple turbine-powered helicopters and fixed-wing aircraft, including turboprops and business jets. Prior to and during this time period, he was a FAA licensed Private Pilot. Jesse also recently contributed a chapter, “THC & CBD Decomposition and Terpene Hazards While Vaping or Dabbing”, to the medical text book edited by Dr. Ken Finn, “Cannabis in Medicine, and Evidence Based Approach”. He also has written articles for the parent support group, Every Brain Matters, one of which was an expose’ on Delta-8-THC, Delta-9-THC, and THC-O Acetate.

In this session, attendees will impart a basic understanding of combustion science and why smoke, regardless of the source, can be harmful to the human body in so many ways. Jesse will discuss the vaporization of cannabinoids and the possible impacts on the lungs, and finally, prove the folly of using combustion or vaporization to deliver “medicine”

Moderated by: Kenneth Finn

Date: April 19, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Eric Voth

Dr. Voth is a specialist in Internal Medicine, Pain Management, and Addiction Medicine and was formerly Vice-President of Primary Care at Stormont-Vail HealthCare in Topeka, Kansas. He serves as the President and Chairman of the Board of the International Academy on the Science and Impact of Cannabis (IASIC). Dr. Voth is a pioneer in the appropriate prescribing of controlled medications and is recognized as an international authority on drug use, drug policy-related issues, pain management, and appropriate prescribing practices.

Dr. Voth also serves as an advisor on alcohol and drug abuse issues to the Kansas State Board of Healing Arts, is a former member of the National Advisory Committee for the Center for Substance Abuse Treatment of HHS, and is a Clinical Professor of Internal Medicine at the University of Kansas School of Medicine.

Dr. Voth has advised Reagan, Clinton, both Bush, and Obama administrations, and has advised or testified for numerous Congressional offices on drug related issues. He has appeared on or consulted to, numerous other radio media, and has been quoted by numerous international print media.

In this session, Dr. Voth will discuss the elements of the Medical Standard of Care that providers must apply to the medicinal applications of Cannabis when recommending it to patients.

Moderated by: Catherine Antley

Date: April 26, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: William Lynch, Jr.

William J. Lynch Jr. received his pharmacy degree from Rutgers University and is a practicing clinical pharmacist with Jefferson Health System where he is a member of the Pain Management & Addiction Committee. He serves as Adjunct Faculty at the Rowan University School of Osteopathic Medicine, Department of Emergency Medicine. His pharmacy background includes over 34 years of clinical practice at Jefferson and Rowan and also as Adjunct Faculty Clinical Preceptor for Rutgers University, Ernest Mario School of Pharmacy and Thomas Jefferson University College of Pharmacy. He is a clinical scientific expert member of the Office of National Drug Control Policy, High Intensity Drug Trafficking Area, National Marijuana Initiative Speakers Bureau (ONDCP HIDTA NMI) and the International Academy on the Science and Impact of Cannabis (IASIC). He is also a health care professional partner of the Keep Delaware Safe & Healthy Coalition, the State of Delaware Substance Abuse Epidemiological Outcomes Working Group and the Central Virginia Overdose Working Group. Bill serves as an Advisory Board Member with atTAcK addiction and is also a member of the Camden County New Jersey Addiction Awareness Task Force where he serves as the Education and Prevention Committee Co-Chair. He is a certified State of New Jersey Department of Law and Public Safety Division of Criminal Justice Police Training Commission Instructor. He also serves as the Gloucester Township Police Department SAVE Program Adviser and as a New Jersey State Police Regional Operations Intelligence Center Drug Monitoring Initiative Fusion Center partner and Health and Prevention Sharing Network partner.

Moderated by: Libby Stuyt

Date: May 3, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: John Searles

John S. Searles, Ph.D. was the Substance Abuse Research and Policy Analyst and Chair of the State Epidemiological Outcomes Workgroup for the Division of Alcohol and Drug Abuse Programs in the Vermont Department of Health.   He retired in 2019.  He is currently an appointed member of the legislatively mandated Substance Misuse Prevention Advisory Council and serves on the council’s Equity, Prevention, and Policy subcommittees.  He has been on the faculty at University of California, Berkeley, the University of Pennsylvania, and the University of Vermont.  He has co-edited two books (“Children of Alcoholics” and “Alcohol and the Family”) and published over 50 scientific articles in the substance use/abuse field.  John earned his doctorate in psychology from the University of California, Berkeley. 

Moderated by: Catherine Antley

Date: May 17, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: E. Alfonso Romero-Sandoval

Dr. Romero-Sandoval received a medical degree from Centro Universitario de Occidente, Quetzaltenango (Universidad de San Carlos de Guatemala) in 1999 and a Ph.D. degree in Neuroscience from Universidad de Alcalá de Henares, Spain, in 2003. He completed postdoctoral trainings at Wake Forest University, Winston Salem, NC (2003-2006) and Geisel Dartmouth Medical School, Lebanon, NH (2006-2007). Dr. Romero-Sandoval has held academic positions (2007-2012) at Geisel Dartmouth Medical School, and served as Director of Research (2013-2017) at Presbyterian College School of Pharmacy in Clinton, SC.
Currently, Dr. Romero-Sandoval is an Associate Professor in Anesthesiology at Wake Forest University School of Medicine. The Romero-Sandoval laboratory explores neuroimmune interactions in surgical and neuropathic pain but also in neuropathies induced by diabetes or chemotherapy. The current major focus of his lab is placed on phenotypic changes in immune cells governed by endoplasmic reticulum or mitochondria function and dysfunction. Additionally, Dr. Romero-Sandoval studies the endocannabinoid system and cannabinoids in the context of pain, and more recently his lab explores how the cannabis market in the U.S. is shaped and how this could affect patients that use cannabis as an alternative to current ineffective pain medications. The Romero-Sandoval laboratory uses highly translatable clinical approaches such as nanotechnology for potential cell-directed gene therapies, functional assays using primary human cells, clinical data, or studies on marketing practices to develop more effective and safer strategies to treat chronic pain.

Moderated by: Libby Stuyt

Date: May 24, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Luke Niforatos

Luke Niforatos serves as the Executive Vice President at SAM, described by the New York Times as the “well-coordinated opposition” to legalization. Luke’s background is in nonprofit community healthcare, having helped manage Federally Qualified Health Centers and worked on health disparities. Prior to joining SAM, Luke was also the Co-Founder of DocBuddy, a healthcare start-up based in Denver, Colorado that he later sold. At SAM, Luke serves as the principal deputy to the CEO in his roles, manages the day to day operations of the organization, and serves as a spokesman on marijuana issues.

In 2018, he was the campaign manager for the successful ballot campaign to defeat legalization in North Dakota, and led SAM’s legislative victories in more than two dozen states. He has been featured at The Economist’s Cannabis Summit as well as the United Nations’ Commission on Narcotic Drugs, and in dozens of events and town halls across the country on the subject of drug policy. He has also been featured in many national media outlets, including Fox News and CNBC, and his op-eds are regularly published across the country. Luke graduated from the University of Denver, and his home state of Colorado gives him a unique vantage point on the issue of sound drug policy.

Today’s marijuana is much more potent than in the past — with pot edibles, candies, cookies, ice creams, and waxes being up to 99% THC. In comparison, marijuana in the Woodstock era contained 5% THC. Luke Niforatos will take participants through the latest facts and figures on what is really happening in legalized states and the overall goal of the legalization movement.

Moderated by: Kenneth Finn

Date: May 31, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Stig Erik Sørheim

Stig Erik Sørheim is head of the international department of Actis – Norwegian Policy Network on Alcohol and Drugs. He is currently president of EURAD Asbl, a European policy network for prevention, treatment, rehabilitation and recovery.
In his work he follows international alcohol and drug policy on the European and global level. He is on the board of several European and regional alcohol, drug and gambling policy networks. He has also been the vice-chair of the European Civil Society Forum on Drugs.

He was formerly a senior adviser in the Norwegian Directorate of Health, working on alcohol and drug issues and social inequalities in health.
He earned his Cand. Philol. degree in the humanities at the University of Oslo.

This session will give an overview of cannabis policy in Europe with special emphasis on recent developments in countries like Malta, Germany, Switzerland and the Netherlands. The presentation will also address the evolution of the medical cannabis market and legal cannabinoids like CBD, and the role of the legal cannabis industry as a driver for policy change.

Moderated by: Kenneth Finn

Date: July 28, 2022
Time: 6:00PM - 7:00PM Eastern / 3:00PM - 4:00PM Pacific

Presented by: Janni Leung

Dr Janni Leung is a Senior Research Fellow at National Centre For Youth Substance Use Research (NCYSUR) at The University of Queensland, Australia. Her program of research includes investigating the epidemiology of substance use and mental health because they are both major public health issues that commonly occur together. This research program had made paradigm changing development through 100+ articles, which have recognised impact (15,000+ cites, 30% output in the top 1% citation percentile). Many of her work involves conducting systematic reviews, meta-analyses, and applying statistical models to epidemiological data on addiction and mental health issues to better understand their impacts on populations. Her work is used to inform policies on how to reduce the disease burden caused by addiction and mental health problems in Australia and overseas.

Moderated by: Kenneth Finn

Date: July 5, 2022
Time: 1:00PM - 2:00PM Eastern / 10:00AM - 11:00AM Pacific

Presented by: Jo McGuire

Jo McGuire is a known advocate for safe and drug free workplaces, families and communities with over ten years of experience in the drug and alcohol testing industry. She was appointed to serve on the Taxation, Banking & Civil Law work-group for the Governor’s Task Force to regulate Amendment 64 in Colorado due to her expertise in the field of workplace drug and alcohol testing and represented the industry during the United Nations General Assembly on the World Drug Agreements. As a recognized subject matter expert, Jo is a highly requested national conference speaker, writer and public policy advisor. 

Moderated by: Libby Stuyt